FindTrial
Sign In

Cerdulatinib

DRUG3 trials

Sponsors

Alexion Pharmaceuticals, Inc., Portola Pharmaceuticals

Conditions

AITLALCLAggressive NHL (a NHL)B-cell Non Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)EATL I,IIFollicular Lymphoma (FL/Indolent NHL)Follicular T-cell Lymphoma (FTCL)

Phase 1

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
CompletedNCT01994382
Alexion Pharmaceuticals, Inc.Aggressive NHL (a NHL), B-cell Non Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) +2
Start: 2013-08-30End: 2020-12-15Updated: 2022-04-05

Phase 2

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
WithdrawnNCT04021082
Portola PharmaceuticalsAITL, ALCL, EATL I,II +6
Start: 2019-11-15End: 2023-06-01Updated: 2023-02-21

Unknown Phase

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
NCT04757259
Alexion Pharmaceuticals, Inc.Non-hodgkin's Lymphoma, Relapsed/Refractory Chronic Lymphocytic Leukemia
Updated: 2024-03-19

Related Papers

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma2025-02-087 citations
Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Blood2021-11-058 citations
Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
Blood2021-11-055 citations
Abstract IA21: Biomarker-informed studies in peripheral T-cell lymphoma
Blood Cancer Discovery2020-11-01
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
Clinical Cancer Research2018-10-1738 citations
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
Journal of Clinical Oncology2018-05-208 citations
Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral t cell lymphoma (PTCL).
Journal of Clinical Oncology2018-05-205 citations
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study
Blood2017-12-07
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
Clinical Cancer Research2016-10-0364 citations
Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies—Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing.
Journal of Clinical Oncology2016-05-20
Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity.
Journal of Clinical Oncology2015-05-206 citations
The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
2014-09-2465 citations
Pharmacokinetics and pharmacodynamics of the dual syk/jak inhibitor PRT062070 (cerdulatinib) in patients with advanced B-cell malignancies.
Journal of Clinical Oncology2014-05-202 citations